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INTRODUCTION
Non-small cell lung cancer (NSCLC) remains the
leading cause of cancer-related mortality world-
wide (1). Although the standard treatment for pa-
tients with metastatic NSCLC is the platinum-based
chemotherapy, it produced only a modest survival
benefit (2, 3). On the other hand, newly developed
tyrosine kinase inhibitors targeting the epidermal
growth factor receptor (EGFR), such as gefitinib
and erlotinib, have shown remarkable activity in
a portion of patients with NSCLC (4). However,
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life-threatening interstitial lung disease (ILD) re-
lated to gefitinib has previously been identified as
the most problematic toxicity of this drug, with an
incidence of ILD caused by gefitinib thought to be
around 4% and with about one-third of the cases be-
ing fatal in Japan (5-7). Risk factors for ILD, such as
male sex, smoking, and the existence of idiopathic
pulmonary fibrosis, have been identified in a num-
ber of retrospective and prospective studies of Japa-
nese gefitinib-treated NSCLC patients (5-7). One of
these studies suggested that history of prior radio-
therapy also seem to be a predictive risk factor for
ILD development (8).
Meanwhile, definitive thoracic radiation therapy
(TRT) in combination with chemotherapy is the
current standard of care for patients with unre-
sectable locally advanced NSCLC, corresponding to
around one-third of individuals with newly diag-
nosed NSCLC. However, TRT also induces injury to
normal lung tissue, causing radiation pneumonitis
(inflammation of the lungs due to radiation) (9). The
injury of capillary endothelial cells and epithelial
cells, which have the highest mitotic rate and are
the most susceptible cells in the lung to radiation,
is believed to initiate alveolar edema, exudation, and
vascular congestion (10, 11). Radiation fibrosis is a
sequel of radiation pneumonitis, as an excessive and
detrimental over-healing (12, 13).
Although the concurrent chemo-radiotherapy is
the gold standard of the treatment for unresectable
locally advanced NSCLC, most treated individuals
experience disease recurrence, with the 5-year sur-
vival rate being only around 20% (14, 15). Further
improvement in treatment outcome for patients with
locally advanced NSCLC will require the develop-
ment of more effective combined-modality thera-
pies. Although the preclinical models have shown
that EGFR inhibition enhances the antitumor activity
of radiation (16, 17), a feasibility study, conducted
by the West Japan Thoracic Oncology Group, to
examine the safety and toxicity profile of gefitinib
with concurrent TRT in patients with unresectable
NSCLC was closed early because of pulmonary tox-
icity (18).
These lines of evidence suggest that gefitinib en-
hances radiation-induced pulmonary toxicity, how-
ever, the mechanism how gefitinib affects radiation
pneumonitis and fibrosis has not been clarified. In
this study, we developed an experimental model of
radiation-induced lung injury and subsequent pul-
monary fibrosis and investigated the effect of gefit-
inib on different phases of this disorder.
MATERIALS AND METHODS
Animals
Specific-pathogen-free male Wistar rats were ob-
tained from the Tokushima Experimental Animal
Laboratory (Tokushima, Japan) and they were
housed in a laminar flow facility and allowed steril-
ized food and water. The rats suffered no pathogenic
infection during the study. Experimental protocol
was reviewed and approved by animal care and use
committee of the University of Tokushima, and all
animal experiments were performed according to
its guidelines.
Designs for animal experiment, thoracic irradiation
and gefitinib treatment
The rats were randomly assigned to 1 of 4 experi-
mental groups : 1) the unirradiated rats treated with
oral administration of vehicle (0.1% Tween 80) once
daily ; 2) the unirradiated rats treated with oral ad-
ministration of gefitinib (50 mg/kg/day) once daily ;
3) the irradiated rats treated with oral administra-
tion of vehicle once daily ; and 4) the irradiated rats
treated with oral administration of gefitinib once
daily. Each experimental group comprised 5-6 rats
and all treatments were delivered for 14 days. Tho-
racic irradiation was administered as described pre-
viously (19, 20). Briefly, the rats weighing 180-200
g were lightly anesthetized with an intraperitoneal
injection of sodium pentobarbital and confined to a
plastic molded frame so that both lungs were in
the field defined by lead collimators. Simulation X
rays determined the accuracy of positioning. The
thoraxes were irradiated on day 1 with a single dose
of 20 Gy using X-ray equipment (MBR-1520R3,
Hitachi Medico Technology, Tokyo, Japan). The
radiation parameters were as follows : a dose-rate
of 3.8 Gy per minute at 150 kV and 20 mA (0.5
mmCu+0.5 mmAl). The unirradiated rats were anes-
thetized and exposed to the same room for the
same period as the animals undergoing irradiation.
Gefitinib (50 mg/kg/day ; Astra Zeneca, Maccles-
field, UK) was suspended in 0.1% Tween 80 solu-
tion and given once daily by oral gavage from day
1 to day 14 after irradiation in the rats with gefitinib
treatment groups. Similarly, vehicle (0.1% Tween
80) alone was administered in the rats without ge-
fitinib treatment groups.
Bronchoalveolar lavage and bronchoalveolar cell
analysis
The lungs were harvested together with other
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thoracic organs from the rats in each experimental
group on days 15 and 57 after irradiation. The tra-
chea was cannulated with plastic catheter attached
to a 6-ml syringe, and bronchoalveolar lavage (BAL)
fluid was collected in a total volume of 30 ml of
sterile saline across five 6-ml samples with gentle
massaging of the lungs. The BAL fluid was com-
bined, passed through a sterile gauze, and centri-
fuged at 1200 rpm for 10 mins at 4to precipitate
the cells it contained. The precipitated cells obtained
from the BAL fluid were suspended in an appropri-
ate volume of RPMI-1640 (Nissui Pharmaceutical
Co., Tokyo, Japan) and counted in a hemocytome-
ter. Differential counts of 500 cells were carried out
on smears of sedimented cells stained with Diff-
Quik solution (International Reagents Co., Kobe,
Japan), and the percentages of alveolar macro-
phages, lymphocytes, neutrophils, and eosinophils
were calculated.
Assay for cytokines
The BAL cells dissolved in RPMI-1640 containing
fetal calf serum (FCS ; GIBCO, Grand Island, NY)
at a concentration of 5.5105 /ml were incubated
for 48 hrs in 24-well tissue culture dishes (Falcon
Plastics, Oxnard, CA) at 37in a humidified atmos-
phere of 5% CO2 in air. Then, the supernatants were
collected and the concentrations of interleukin (IL)-
6 and IL-1β were determined by enzyme-linked im-
munosorbent assay (ELISA ; R&D Systems, Min-
neapolis, MN). The assays were set up in duplicate
and performed according to the manufacturer’s rec-
ommendations. The lower limits of detection were
21.0 pg/mL and 5.0 pg/mL for IL-6 and IL-1β, re-
spectively.
Histological examination
Whole non-lavaged lungs were harvested from
irradiated rats on day 0, 15 and 57 after irradiation,
fixed in 10% phosphate-buffered formalin, and em-
bedded in paraffin. Sections of 3-μm thickness were
cut and stained with hematoxylin-eosin (H&E) or
Azan for histological analysis. The sections were
then systematically scanned in a microscope at400
magnification. Cell identification was performed us-
ing the classic definitions of cell shape, nuclear
shape, heterochromatin, nuclear-to-cytoplasmic ra-
tio, cytoplasmic volume, and staining characteristics.
Collagen assay
The right lungs harvested on day 57 were used for
collagen assay. Total lung collagen was determined
using the Sircol Collagen Assay kit (Biocolor Ltd.,
Belfast, Northern Ireland) according to the manu-
facturer’s
The isolation of the rat lung fibroblasts
The rat lung fibroblasts were prepared as de-
scribed previously (21). Briefly, the lungs were har-
vested using sterile instruments, minced into 2-4
mm pieces, suspended in sterile PBS containing
0.5% trypsin, and incubated with gentle stirring for
30 mins at 37. The dispersed cells were then
collected and separated from undigested tissue and
debris by filtration through sterile gauze. Next,
the cells were washed with Dulbecco’s modified
Eagle’s medium (DMEM ; Nissui Pharmaceutical
Co., Tokyo, Japan) containing 10% FCS and then
resuspended in DMEM, before being incubated at
37in a humidified atmosphere of 5% CO2 in air.
After 24-48 hrs, unattached cells were removed by
washing, and fresh media was added. When the tis-
sue culture plates had reached confluence, the cells
were passaged by splitting them 1 : 3. The cells
were then maintained in DMEM containing 10%
FCS and passaged repeatedly. By the fourth pas-
sage, the cells had formed homogenous monolay-
ers that were morphologically consistent with fibro-
blast-like cells. Cell identity was confirmed by posi-
tive vimentin staining and by negative staining of
cytokeratin or CD68. All experiments were under-
taken using cells from the 4th to 10th passage. Fi-
broblasts from irradiated and unirradiated rat lungs
were each prepared as five separate lines on days
15 and 57 after irradiation.
Cell proliferation assay
Cell proliferation was determined using the MTT
[3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetra-
zolium] dye reduction method. The fibroblasts were
seeded onto 6-well plates (5104 cells/well) and
maintained in DMEM containing 10% FCS for 24,
48, 72, 96, 120, or 144 hrs. At each time point, cell
proliferation was evaluated by the MTT assay using
Cell Counting Kits (WAKO, Osaka, Japan). Briefly,
10 μl of stock MTT solution (5 mg/ml) was added
to all wells of an assay, and the plates were incu-
bated for 4 hrs at 37in a humidified atmosphere
of 5% CO2 in air. Acid-isopropanol (100 μl of 0.04 N
HCl in isopropanol) was added to all wells and
mixed thoroughly to dissolve the dark blue crystals.
After being left for a few minutes at room tempera-
ture to ensure that all crystals had dissolved, the
plates were measured with an MTP-32 Microplate
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Photometer (Corona Electric Co., Ibaragi, Japan)
using a test wavelength of 550 nm and a reference
wavelength of 630 nm.
Quantitative reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNAs of the samples extracted from each
fibroblast line were isolated using the RNeasy Mini
and RNase-free DNase kits (Qiagen, Valencia, CA)
in accordance with the manufacturer’s recommenda-
tions. Total RNAs were reverse transcribed using the
Omniscript RT kit (Qiagen, Valencia, CA), and the
expression of EGFR, COL1A2, and GAPDH was
measured by quantitative RT-PCR analysis on an ABI
7700 Sequence Detection system (Applied Biosys-
tems, Foster City, CA) with the following commer-
cially available sets of primers and fluorogenic probes
(TaqMan Gene Expression Assays products) :
EGFR, Rn01434460_m1 ; COL1A2, Rn00670322_g1 ;
GAPDH, Rn01775763_g1. The quantitative RT-PCR
experiments were performed in triplicate, and the
relative expression levels were calculated based on
the comparative Ct method.
Statistical Analysis
All results are expressed as the meanSEM. Sta-
tistical analysis was performed using the Student’s
two-tailed unpaired t test for comparisons between
two groups. Differences were considered significant
when the corresponding p value was 0.05 or less.
Data were analyzed using the Statview software
package.
RESULTS
Body weight changes of the rats
To elucidate the influence of radiation and gefit-
inib, we first examined the body weights of the rats
in each experimental group. Figure 1 shows the
time course of body weight change after irradiation.
A significant decrease in body weight was seen in
the irradiated rats during entire experimental pe-
riod compared with the unirradiated rats. The body
weight of the irradiated rats treated with gefitinib
tended to be decreased compared to those treated
with vehicle during entire experimental period and
a significantly decreased body weight was seen on
day 15 after irradiation. Gefitinib treatment itself did
not affect the body weight in unirradiated rats.
Cellular analysis of the BAL fluids
We previously demonstrated histological changes
in the lungs after a single dose of radiation, which
Figure 1. Rats were irradiated on day 1 with a single dose of 20 Gy using X-ray equipment. Time course of the changes in body
weight in each experimental group. Vehicle plus no radiation (RT) ( ), gefitinib plus no RT ( ), vehicle plus RT ( ), and gefitinib
plus RT ( ). Data are presented as meanSEM. *p0.001 vs. vehicle plus no RT, #p0.001 vs. gefitinib plus no RT, and p0.01
vs. vehicle plus RT, p0.05 vs. vehicle puls RT.
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showed that interstitial pneumonitis occurs 2 weeks
after irradiation, followed by an increase in intersti-
tial lung collagen 8 weeks and later (22). Therefore,
in this study, we examined the BAL fluid on days 15
and 57 after irradiation to test whether gefinitib treat-
ment affects inflammation in the irradiated lungs.
Regarding cell differentiation, the numbers of
neutrophils in the BAL fluids were significantly in-
creased in the irradiated rats on days 15 and 57
compared with the unirradiated rats. Gefitinib treat-
ment significantly increased the numbers of neu-
trophils in BAL fluids in irradiated rats on day15,
but significantly decreased those on day 57 (Figure
2A, B). Similarly, a significantly increased numbers
of lymphocytes in the BAL fluids were observed in
the irradiated rats with gefitinib compared to those
without gefitinib on days 15 and 57 (Figure 2C, D).
Gefitinib treatment itself did not affect the total num-
ber of BAL cells (data not shown) or the cellularity
of the BAL cells in unirradiated rats.
Proinflammatory Cytokines production from the
BAL cells
Several pro-inflammatory cytokines have been re-
ported to contribute to the development of radia-
tion-induced lung disorders (23, 24) and increases
in IL-6 and IL-1β have been found during the de-
velopment of alveolitis (24, 25). Therefore, we next
measured the concentrations of IL-6 and IL-1β in
the culture medium of BAL cells from the rats in
each experimental group by ELISA. The BAL cells
from the irradiated rats produced significantly more
IL-6 and IL-1β than those from the unirradiated rats
on day 15 after irradiation. Moreover, Gefitinib treat-
ment for rats significantly increased the expressions
of IL-6 and IL-1β from the BAL cells from the irra-
diated rats on day 15 after irradiation. The increased
expression of IL-6 and IL-1β from the BAL cells
from the irradiated rats with gefitinib continued until
day 57 (Figure 3A-D).
Figure 2. The number of neutrophils (A ; day 15, B ; day 57) and lymphocytes (C ; day 15, D ; day 57) in the BAL fluids from each
experimental group. Data are presented as meanSEM (n=3-5 per group). *p0.005 vs. vehicle plus no RT, #p0.05 and ##p
0.0001 vs. gefitinib plus no RT, and p0.05, p0.01 and p0.0005 vs. vehicle plus RT.
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Histological examination
Lung histology showed increased inflammatory
cell infiltration in the lungs on day 15, and severe
lung fibrosis including collagen deposition on day
57 in the irradiated rats without gefitinib treatment
(Figure 4A). The collagen content of the lung was
significantly lower in irradiated rats with gefitinib
treatment compared to the rats without gefitinib
treatment (Figure 4B).
The proliferation of the lung fibroblasts
The lung fibroblasts are well known to have the
most central role in the process of pulmonary fibro-
sis due to their ability to produce collagen. Thus,
we harvested the lung fibroblasts from the rats in
Figure 3. IL-6 (A ; day 15, B ; day 57) and IL-1β (C ; day 15, D ; day 57) expression from the BAL cells. Data are presented as
meanSEM. *p0.01, **p0.005 and ***p0.0001 vs. vehicle plus no RT, #p0.005 and ##p0.0001 vs. gefitinib plus no RT, and
p0.005 and p0.0001 vs. vehicle plus RT.
Figure 4. (A) Typical photomicrographs of H&E and Azan staining of the lungs from irradiated rats without gefitinib treatment on
day 15 or 57 after irradiation. Magnification400. (B) Collagen content of the lungs from irradiated rats with or without gefitinib
treatment on day 57 by Sircol collagen assay. Data are presented as meanSEM. n=5-6.
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each experimental group and compared their pro-
liferation by MTT assay. The proliferation of lung
fibroblasts from the irradiated rats was significantly
increased to a greater extent than those from the
unirradiated rats on days 15 and 57 expectedly. Gefi-
nitib treatment for rats did not change the prolif-
eration of lung fibroblasts from either irradiated and
unirradiated rats on day 15, while gefitinib treat-
ment for rats significantly decreased the prolifera-
tion of lung fibroblasts from irradiated rats on day
57 (Figure 5A, B).
The expression of EGFR and collagen in the lung
fibroblasts
To test whether gefitinib treatment for rats af-
fects EGFR expression in the lung fibroblasts, we
examined EGFR mRNA expression in the lung fi-
broblasts from the rats in each experimental group
on day 57 by quantitative RT-PCR. EGFR mRNA
expressions were detectable in the lung fibroblasts
derived from the rats in either experimental group.
Although EGFR mRNA expression was enhanced
by the irradiation, gefitinib treatment for rats sig-
nificantly decreased EGFR mRNA expression in the
lung fibroblasts from the irradiated rats (Figure 6A).
To test whether gefitinib treatment for rats affects
collagen production from the lung fibroblasts, we
also examined COL1A2 mRNA expression in the
lung fibroblasts from the rats in each experimental
group by quantitative RT-PCR. Although COL1A2
mRNA expression in the lung fibroblasts from the
irradiated rats was significantly greater than in those
from the unirradiated rats, gefitinib treatment for
rats did not decrease COL1A2 mRNA expression in
the lung fibroblasts in either irradiated and unirra-
diated rats (Figure 6B).
Figure 5. The proliferation of the lung fibroblasts from each experimental group obtained on days 15 (A) and 57 (B). Data are
presented as meanSEM. *p0.01 vs. vehicle plus no RT, and #p0.01 vs. gefitinib plus RT.
Figure 6. The expression of EGFR mRNA (A) and COL1A2 (B) mRNA in the lung fibroblasts from each experimental group on
day 57. Data are presented as meanSEM. *p0.01 vs. vehicle plus no RT.
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DISCUSSION
The expression and activity of EGFR are impor-
tant determinants of radiation sensitivity in several
cancers including NSCLC (26, 27). Irradiation of
tumor cells has been shown to activate EGFR via
ligand-dependent and ligand-independent mecha-
nisms, possibly accounting for the radiation-induced
acceleration of tumor cell repopulation and the de-
velopment of radioresistance (27, 28). Such radia-
tion-induced activation of EGFR-dependent proc-
esses provides a rationale for combined treatment
with radiation and EGFR inhibitors. Although a se-
ries of recently published studies showed promis-
ing preclinical evidence regarding the capacity of
EGFR inhibition to enhance the antitumor activity
of ionizing radiation (16, 17), a feasibility to inves-
tigate the tolerability and safety of gefitinib com-
bined with definitive TRT in patients with locally
advanced NSCLC was closed early due to pulmo-
nary toxicity (18). Moreover, the history of prior ra-
diotherapy is known to be a predictive risk factor
for ILD related to gefitinib (8). These findings sug-
gest that gefitinib may enhance radiation-induced
pulmonary toxicity, however, the mechanism how
gefitinib affects radiation-induced pneumonitis and
fibrosis has not been clarified. In this study, we
sought to investigate the effect of gefitinib on dif-
ferent phases of radiation-induced lung disorders
in an experimental model, and demonstrated that
gefitinib augmented inflammation in the lungs, but
attenuated the fibrotic lung remodeling in response
to irradiation injury.
Radiation-induced lung disorder is characterized
by interstitial edema, interstitial and alveolar inflam-
matory cell infiltration (11, 12), and subsequent fi-
brotic reaction characterized by the proliferation of
fibroblasts and deposition of extracellular matrix
(13). The recruitment and activation of inflamma-
tory cells, such as neutrophils and lymphocytes, are
central elements in the development of radiation-
induced interstitial pneumonitis (22, 23, 29). Neu-
trophils are the first responding cells in lung tissues
injured by irradiation (23). Lymphocytic alveolitis
is a well-recognized component that occurs in re-
sponse to tissue injury caused by irradiation, and a
prominent feature of post-radiation lung injury is
the development of lymphocytic alveolitis (19, 30).
We have also shown the characteristic histological
changes of lymphocytic alveolitis after irradiation
(19, 22). In this study, the irradiated rats treated
with gefitinib showed significantly lower body
weights than those treated without gefitinib on day
15. Moreover, gefitinib treatment increased the num-
bers of neutrophils and lymphocytes on day 15.
These findings suggested that gefitinib augmented
the extent of lung injury and interstitial pneumonitis
caused by irradiation (Figure 7). On the other hand,
gefitinib treatment decreased the number of neu-
trophils, but not that of lymphocytes on day 57. Ge-
finitib may have direct effects on the neutrophil
population that are different from the early phase,
or activated fibroblasts may affect the recruitment
or proliferation of neutrophils in the late stage of fi-
brosis. The finding is a target of future experiment.
Several lines of evidence have indicated the con-
tribution of pro-inflammatory cytokines to the de-
velopment of radiation-induced lung disorders (23,
24). Increases in IL-6 and IL-1β have been found
during the course of the development of alveolitis
in both patients and animal models (24, 25). In the
present study, gefitinib treatment significantly in-
creased the production of IL-6 and IL-1β from the
BAL cells from the irradiated rats in both the early
(day 15) and late phases (day 57) of radiation-in-
duced lung disorders, indicating that gefitinib in-
creased the production of pro-inflammatory cytoki-
nes, which might be responsible, at least in part, for
the increased lung injury and inflammation induced
by irradiation.
The mechanism responsible for the increased in-
flammation induced by gefitinib in radiation-induced
lung disorders is uncertain. Gefitinib has been shown
to inhibit the proliferation of EGFR-expressing cells
such as alveolar epithelial cells, resulting in the in-
hibition of the anti-inflammatory response by these
Figure 7. The effect of gefitinib on radiation injury of the lung.
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cells following lung injury (31). Therefore, our re-
sults suggest that EGFR inhibition for epithelial cells
by gefitinib might suppress normal repair from tis-
sue injuries caused by irradiation, leading to pro-
longed inflammation.
Although severe alveolar injury induced by a
variety of agents has been shown to disturb normal
epithelial-fibroblast interactions, resulting in exces-
sive collagen production and the development of pul-
monary fibrosis (32, 33), the present study showed
collagen content of the lung was decreased in spite
of the increased inflammation in the lung of irradi-
ated rats with gefitibib, which indicates that gefit-
inib attenuates radiation-induced lung fibrosis. The
EGFR and its ligands are known to have an impor-
tant role in the pathogenesis of pulmonary fibrosis.
The EGFR expression was reported to be increased
in the lung by bleomycin-induced lung injury in rats
(34). Transforming growth factor-α (TGF-α) was
also increased in the lung of idiopathic pulmonary
fibrosis (35), and TGF-α knockout mice displayed
significantly reduced lung collagen accumulation
following bleomycin-induced injury (36). In the pre-
sent study, increased EGFR expression and faster
proliferation were found in fibroblasts from the ir-
radiated rats than in those from the unirradiated
rats. However, gefitinib treatment decreased the
EGFR expression and the proliferation in fibroblasts
from the irradiated rats, suggesting that the de-
creased response to growth factors due to the down-
regulation of EGFR by gefitinib treatment resulted
in decreasing the proliferative ability of lung fibro-
blasts. The decreased proliferative ability in lung fi-
broblasts from the irradiated rats with gefinitib treat-
ment may explain the finding that gefitinib treat-
ment attenuated radiation-induced lung fibrosis. Our
result is supported by a previous study reported by
Wang et al , in which a high dose (200 mg/kg/day)
of gefitinib administered during the late phase (days
14 to 19) reduced fibrosis score and collagen levels
in the lungs of irradiated mice, but the administra-
tion during acute phase (days 0 to 5) and the low
dose administration during late phase did not (37).
A study by Suzuki et al reported that gefitinib
treatment augment lung fibrosis in BLM-treated
mice and that gefitinib did not inhibit the prolifera-
tion of lung fibroblasts in vitro experiments (31),
which are not consistent with the results reported
by Wang et al and our findings that gefitinib treat-
ment attenuated lung fibrosis in irradiated rats and
that gefitinib treatment for rats decreased the prolif-
erative ability of lung fibroblasts from the irradiated
rats. These results suggest that EGFR inhibitor may
have conflict functions in lung fibrosis development,
which may depend on which cell type is regulated
by gefitinib. Inhibition of fibroblast proliferation may
attenuate lung fibrosis, while inhibition of epithelial
cell proliferation may augment lung fibrosis. The
discrepancy between these studies may depend on
the difference in the experimental systems, includ-
ing the use of the BLM model in the Suzuki et al
study and the RT model in Wang’s and our studies.
Lung injury induced by a single dose of irradiation
might be mild for a drug intervention experiment.
In addition, in this experimental model, chronic lung
injury and fibrosis were longer lasting than in BLM
model, in which lung fibrosis development may de-
pend on fibroblast activation dominantly rather than
decreased epithelial integrity. However, further stud-
ies are necessary to clarify the mechanism of the
different effect of gefitinib treatment in lung fibrosis
development in each experimental model.
Gefitinib treatment changed the proliferative abil-
ity of lung fibroblasts, while the treatment did not
change the collagen production ability of lung fi-
broblasts, which suggests that gefitinib treatment
does not affect fibroblast differentiation into myofi-
broblast. Therefore, the decreased collagen content
in the lungs of irradiated rats with gefitinib treatment
may depend on the decreased number of lung fibro-
blasts due to the decreased proliferative ability.
A phase I study designed to assess the safety of
concomitant cetuximab, a monoclonal antibody that
binds EGFR and radical RT in patients with inoper-
able Stage III NSCLC showed that the early and late
toxicities of concomitant cetuximab and radical RT
were acceptable (38). An ongoing radiation therapy
oncology group (RTOG) trial, RTOG 0324, is evalu-
ating the combination of cetuximab with RT in unre-
sectable stage III NSCLC patients (38). The interim
analysis showed improvement in overall survival
(OS) compared to historical controls (response rate
62% (n=54), median survival 22.7 months and 2-
year OS of 49.3%). In our study, gefitinib treatment
has augmented interstitial pneumonitis and inflam-
mation in the lungs especially on early phase in
rats. Administration of gefitinib concurrent with tho-
racic irradiation might be harmful by increasing the
risk of pneumonitis. Gefitinib treatment combined
with definitive TRT for patients with locally advanced
NSCLC had better be avoided due to its greater risk
of pulmonary toxicity. Sequential gefitinib treatment
after thoracic irradiation should be also considered
carefully, but might be acceptable and useful for
K. Miyake, et al. Gefitinib in radiation pneumonitis182
patients with locally advanced NSCLC, when con-
sidering the safety of cetuximab combined with RT
and our finding of anti-fibrotic effect of gefinitib in
RT model on late phase. When we try sequential
gefinitib treatment after thoracic irradiation, the in-
terval until gefitinib treatment after irradiation may
be essential, and a clinical trial should be planned.
In addition, it is a future experiment in animal model
whether sequential gefinitib treatment after irradia-
tion is acceptable and useful.
In summary, the present study demonstrated
that gefitinib treatment augmented interstitial pneu-
monitis, but attenuated fibrotic lung remodeling in
response to irradiation injury. Gefitinib treatment
concurrent with thoracic irradiation had better be
avoided due to its greater risk of pulmonary toxicity,
while sequential gefitinib treatment after thoracic
irradiation might be acceptable and useful for pa-
tients with locally advanced NSCLC.
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